← All trials
NCT06652997
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2022
- Primary completion
- Aug 14, 2022
- Completion date
- Nov 2, 2022
- First posted
- Oct 22, 2024
- Last posted
- Oct 22, 2024
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sichuan UniversityLead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdCollaborator
- Government of ChinaOfficial
- Sichuan UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.